DurgicalDurgical
EN
Open the app

Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) !

Fake DNA building blocks: HIV reverse transcriptase adds them and the viral DNA chain stops. They form the backbone of almost every HIV regimen.

Updated 2026-11-01

What they are

Nucleoside analogues (abacavir, lamivudine, emtricitabine, zidovudine) or nucleotide analogues (tenofovir), usually given as a pair forming the regimen's backbone, together with a third drug from another class (today usually an integrase inhibitor).

Mechanism of action

They are prodrugs: cellular kinases phosphorylate them to the triphosphate form (diphosphate for tenofovir). Reverse transcriptase mistakes them for natural nucleotides and adds them to viral DNA; lacking a 3'-hydroxyl group, no further nucleotide can be joined and the chain terminates. Some also inhibit human mitochondrial DNA polymerase γ, the source of the mitochondrial toxicity of older agents.

Target: HIV reverse transcriptase (polymerase active site)

Drugs in this class

Others in the class

  • Stavudine (withdrawn in many countries)
  • Didanosine (withdrawn in many countries)

Test yourself

Think of the answer, then tap the question to see it.

Why do NRTIs stop viral DNA synthesis?

Once phosphorylated, reverse transcriptase incorporates them into DNA, but they lack the 3'-hydroxyl needed to join the next nucleotide, so the chain terminates.

Which NRTI requires a genetic test before starting, and which test?

Abacavir: testing for the HLA-B*5701 allele, which predicts a severe hypersensitivity reaction.

What risk do lamivudine, emtricitabine and tenofovir share in a person with hepatitis B?

A severe acute flare of hepatitis B when they are stopped, because they also suppress that virus.

Which human enzyme explains NRTI mitochondrial toxicity?

Mitochondrial DNA polymerase γ, which some NRTIs also inhibit; it shows up as lactic acidosis, steatosis or myopathy.

Add to my cards (4)

← All of pharmacology

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 64 (McGraw Hill, 2023); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026); WHO recommends dolutegravir as preferred HIV treatment option in all populations (World Health Organization, 2019).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.